1. Home
  2. BST vs NVAX Comparison

BST vs NVAX Comparison

Compare BST & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Science and Technology Trust of Beneficial Interest

BST

BlackRock Science and Technology Trust of Beneficial Interest

HOLD

Current Price

$40.72

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.25

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BST
NVAX
Founded
2014
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
BST
NVAX
Price
$40.72
$9.25
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$10.78
AVG Volume (30 Days)
103.1K
5.4M
Earning Date
01-01-0001
02-26-2026
Dividend Yield
10.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.07
Revenue
N/A
$1,064,651,000.00
Revenue This Year
N/A
$58.91
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$4.71
Revenue Growth
N/A
20.27
52 Week Low
$27.87
$5.01
52 Week High
$44.50
$10.65

Technical Indicators

Market Signals
Indicator
BST
NVAX
Relative Strength Index (RSI) 51.16 64.79
Support Level $39.80 $7.73
Resistance Level $41.44 $10.13
Average True Range (ATR) 0.58 0.61
MACD -0.03 0.22
Stochastic Oscillator 49.46 69.08

Price Performance

Historical Comparison
BST
NVAX

About BST BlackRock Science and Technology Trust of Beneficial Interest

BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: